Hematologic Oncology

Jessica K. Altman, MD, and Naval G. Daver, MD, share their approaches to genetic testing for FLT3 and other actionable mutations in acute myeloid leukemia (AML).

A review of data from the COMFORT trials and the management and real-world use of ruxolitinib in patients with myelofibrosis, also touching on its use during the coronavirus pandemic.

Srdan Verstovsek, MD, PhD, reviews data from the JAKARTA and JAKARTA2 clinical trials as well as his approach to using fedratinib in his own clinical practice. 

The FDA has approved a revised label for daunorubicin/cytarabine (Vyxeos) to include the treatment of pediatric patients aged 1 year and older with newly diagnosed, therapy-related acute myeloid leukemia (AML) or AML with myelodysplasia-related changes.

Gilteritinib was found to result in a significant improvement in overall survival when used in patients with FLT3-mutated, relapsed/refractory acute myeloid leukemia, meeting the primary end point of the confirmatory phase 3 COMMODORE trial in China.

The National Comprehensive Cancer Network guidelines for the management of frontline and relapsed/refractory multiple myeloma were updated to incorporate novel agents and combination strategies, providing a wide range of category 1 recommended therapies for patients.

Japan’s Ministry of Health, Labour and Welfare has approved lisocabtagene maraleucel, a CAR T-cell therapy designed to target CD19, for the treatment of patients with relapsed or refractory large B-cell lymphoma, as well as relapsed/refractory follicular lymphoma.

The rolling submission of a biologics license application to support the approval of ublituximab plus umbralisib as a treatment for patients with chronic lymphocytic leukemia has been completed.

Nikhil C. Munshi, MD, discusses the FDA approval of idecabtagene vicleucel for patients with relapsed/refractory multiple myeloma after 4 or more prior lines of therapy, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody.

Aditi Shastri, MBBS, discusses risk stratification tools, her treatment algorithm for patients with low-risk MDS, and the role of luspatercept in this population.

A panel of hematologist-oncologists share best practices for managing a 68-year-old male with relapsed/refractory follicular lymphoma who is under consideration for treatment with tazemetostat.

Andrew M. Evens, DO, MSc, FACP, of Rutgers Cancer Institute of New Jersey, comments on the rationale for testing for EZH2 mutations in relapsed/refractory follicular lymphoma.

The expert panel considers the time frame of transplant-associated thrombotic microangiopathy, the subtle signs to pay attention to, and testing for proteinuria.

A panel of experts in hematopoietic stem cell transplantation examine their personal experience in the incidence of transplant-associated thrombotic microangiopathy in the adult and pediatric populations and the criteria used to diagnose.

Ruben A. Mesa, MD, and Srdan Verstovsek, MD, PhD, provide insight on the disease burden and prognostic scoring of primary myelofibrosis, as well as options for nontransplant candidates.

Srdan Verstovsek, MD, PhD, shares how he assesses and typically starts treatment in patients with low-risk primary myelofibrosis, looking specifically at whether patients are symptomatic or asymptomatic. 

The 3 most common types of amyloidosis––TTR mutant, TTR wild-type, and amyloid light chain––have a significant amount of cardiac involvement, making cardiologists essential players in the diagnostic workup and treatment of these patients

Takeaways of safety and efficacy data published on tazemetostat, an EZH2 inhibitor, to treat relapsed/refractory follicular lymphoma, and implications for using the drug in clinical practice.

Drs Andrew M. Evens and Loretta J. Nastoupil remark on the recent approval of tazemetostat, an EZH2 inhibitor, as treatment for relapsed/refractory follicular lymphoma and highlight which types of patients are most appropriate to manage with this drug.

Kira Gritsman, MD, PhD, discusses several novel agents that are under investigation to improve outcomes in poor-prognosis subsets of patients with AML, early data supporting these approaches, and the potential impact of these options on the treatment paradigm.

Alex Herrera, MD, discusses the potential role of camidanlumab tesirine in patients with relapsed/refractory Hodgkin Lymphoma, which is currently being examined in a phase 2 clinical trial.

Peter Martin, MD, discusses selecting among BTK inhibitors for the treatment of patients with mantle cell lymphoma.

Ghaith Abu-Zeinah, MD, discusses utilizing interferon-alpha in patients with polycythemia vera.

Jerald Radich, MD, highlights the role minimal residual disease in acute myeloid leukemia, how different technological advanced have increased the application of MRD-based strategies, and ongoing efforts that are being made to address remaining questions.

Matthew Lunning, DO, discusses discussed the findings from pivotal CAR T-cell therapy trials in LBCL, the potential to utilize these agents in the outpatient setting, how off-the-shelf allogeneic products could further transform outcomes, and the importance of shortening brain-to-vein time for this patient population.